Search
Stories, the companies and people Loro tracks, and the primary records behind them — filings, donations, contracts and disclosures.
Company or person10
AIM ImmunoTech Inc.
Company
Immunome Inc.
Company
Immunovant, Inc.
Company
IMMUNIC, INC.
Company
XBiotech Inc.
Company
Imunon, Inc.
Company
Altimmune, Inc.
Company
CitroTech Inc.
Company
ImmunityBio, Inc.
Company
FDCTECH, INC.
Company
Primary record16
AIM ImmunoTech Inc. filed 4
SEC form 4 filed by AIM ImmunoTech Inc. (CIK 946644) on 2026-11-06.
AIM ImmunoTech Inc. filed 8-K
Item 7.01 Regulation FD Disclosure. Furnished herewith as Exhibits 99.1 and 99.2, respectively, are a Corporate Presentation of AIM ImmunoTech Inc. (the “Company”) titled “The Ampligen Opportunity” and a press release is
AIM ImmunoTech Inc. filed 4
SEC form 4 filed by AIM ImmunoTech Inc. (CIK 946644) on 2026-10-26.
AIM ImmunoTech Inc. filed 4
SEC form 4 filed by AIM ImmunoTech Inc. (CIK 946644) on 2026-10-23.
AIM ImmunoTech Inc. filed DEF 14A
SEC form DEF 14A filed by AIM ImmunoTech Inc. (CIK 946644) on 2026-09-30.
AIM ImmunoTech Inc. filed 4
SEC form 4 filed by AIM ImmunoTech Inc. (CIK 946644) on 2026-09-18.
AIM ImmunoTech Inc. filed 4
SEC form 4 filed by AIM ImmunoTech Inc. (CIK 946644) on 2026-09-17.
AIM ImmunoTech Inc. filed 4
SEC form 4 filed by AIM ImmunoTech Inc. (CIK 946644) on 2026-09-16.
AIM ImmunoTech Inc. filed 4
SEC form 4 filed by AIM ImmunoTech Inc. (CIK 946644) on 2026-09-15.
AIM ImmunoTech Inc. filed 8-K
Item 1.01 Entry into a Material Definitive Agreement. From September 8, 2026 to September 9, 2026, AIM ImmunoTech Inc. (the Company ) entered into a total of two exchange agreements (the Exchange Agreements ) and, for ea
AIM ImmunoTech Inc. filed 8-K
Item 1.01 Entry into a Material Definitive Agreement. On September 3, 2026 and September 4, 2026, AIM ImmunoTech Inc. (the Company ) entered into a total of two exchange agreements (the Exchange Agreements ) and, for eac
AIM ImmunoTech Inc. filed 8-K
Item 1.01 Entry into a Material Definitive Agreement. On August 31, 2026 through September 3, 2026, AIM ImmunoTech Inc. (the Company ) entered into a total of five exchange agreements (the Exchange Agreements ) and, for
AIM ImmunoTech Inc. filed 8-K
Item 7.01 Regulation FD Disclosure. On August 11, 2026, the online media company Breaking Defense ( https://breakingdefense.com ) published an article authored by Thomas K. Equels, the Chief Executive Officer of AIM Immu
AIM ImmunoTech Inc. filed 8-K
Item 2.02 Results of Operations and Financial Condition. On August 10, 2026, AIM ImmunoTech Inc. (the Company ) issued a press release (the Press Release ) announcing its financial results for the quarter ended June 30,
AIM ImmunoTech Inc. filed 8-K
Item 1.01 Entry into a Material Definitive Agreement. On July 31, 2026, AIM ImmunoTech Inc. (the Company ) entered into a proposal (the Proposal Agreement ) with Sterling Pharma Solutions (the Manufacturer ) that is rela
AIM ImmunoTech Inc. filed 8-K
Item 1.02 Termination of a Material Definitive Agreement As previously disclosed, AIM ImmunoTech Inc. (the Company ) is a party to the Equity Distribution Agreement (the Agreement ), dated April 1, 2025, as amended on Ap